

AlzeCure gets late-breaking abstract on ACD440 in neuropathic pain accepted for presentation

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that it has received approval to present an abstract on its lead candidate drug ACD440 for neuropathic pain at the IASP 2021 World Congress on Pain, which this year will be held completely digitally on June 9-11 and June 16-18.

The late-breaking abstract, titled *ACD440 – A potent TRPV1 Antagonist for the topical Treatment of Pain*, will be presented at the biggest global pain conference IASP 2021 World Congress on Pain by Dr. Märta Segerdahl, project leader and CMO at AlzeCure. The other authors include Dr. Klaus Schaffler, who conducted the Proof-of-Mechanism study of ACD440, Dr. Johan Sandin, CSO at AlzeCure, and Matthias Rother, Medical Program Director at AlzeCure.

On April 19, slightly ahead of time, AlzeCure announced positive clinical data from the study, which demonstrate that ACD440, a TRPV1 antagonist and AlzeCure's drug candidate for neuropathic pain within the company's Painless platform, was able to demonstrate positive proof-of-mechanism data, showing analgesic efficacy in man. The observed effects with ACD440 were highly significant over placebo. Also, it was well tolerated as a topical gel on human skin which indicates good suitability for further clinical development, i.e. as a local treatment for neuropathic pain conditions.

"I am very pleased that we once again receive an approval for an abstract with one of our leading candidate drugs, this time from our Painless platform. This is a clear validation of our clinical development platform and strengthens our conviction that we are right in our research and our projects. The new data we have for ACD 440 in neuropathic pain are promising, and we look forward to present it", said Martin Jönsson, CEO of AlzeCure Pharma AB.

The abstract and the poster will be available on AlzeCure's website after the presentation (<https://www.alzecurepharma.se/en/presentations-and-interviews/>).

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.

About Neuropathic pain

Neuropathic pain affects approximately 7–8 percent of the total adult population. Some patients, with indications such as diabetes and HIV, are affected to a greater extent, where approximately 25 and 35 percent respectively of the patients experience neuropathic pain.

Peripheral neuropathic pain is the result of various types of damage to the nerve fibers, such as toxic, traumatic or nerve compression injuries as well as metabolic and infectious diseases. Common symptoms are painful tingling that can be described as "pins and needles", or choking or burning pain, as well as the feeling of getting an electric shock. Patients may also experience allodynia (pain caused by a stimulus that usually does not cause pain) or hyperalgesia (increased pain from a stimulus that normally provokes pain).

The market for neuropathic pain is characterized by a major medical need in all indications and in all major markets, where only about 50 percent of patients respond to existing treatment.

The patient population will grow, among other things, due to an aging population and increased number of long-term cancer survivors and increasing prevalence of type-2 diabetes.

The global market for neuropathic pain was valued at \$5 billion in 2015 and is expected to grow to \$8 billion by 2024.

Attachments

AlzeCure gets late-breaking abstract on ACD440 in neuropathic pain accepted for presentation